

Lund, 24 April, 2023

EQL Pharma AB (publ)

556713-3425

## Offer document regarding EQL Pharma's offer to the shareholders of Sensidose Aktiebolag published

*This announcement is not an offer, whether directly or indirectly, in Australia, Canada, Hong Kong, Japan, New Zealand, Singapore, South Africa or USA, or in any other jurisdiction where such offer pursuant to legislation, restrictions and regulations in such relevant jurisdiction would be prohibited by applicable law. Shareholders not resident in Sweden who wish to accept the Offer (as defined below) must make inquiries concerning applicable legislation and possible tax consequences. Shareholders should refer to the offer restrictions included in the section titled "Important information" at the end of this announcement and in the offer document which has been published in connection with this announcement and in connection with the beginning of the acceptance period for the Offer.*

EQL Pharma AB (publ) ("EQL Pharma") announced on 20 April 2023 a public takeover offer to the shareholders of Sensidose Aktiebolag ("Sensidose") to transfer all shares in Sensidose for SEK 7.60 cash per share. The 24th of April EQL Pharma announced a revised offer, and unconditional, offer with a revised remuneration for the shares, SEK 8.40 (the "Offer"). The offer document is available on EQL Pharma's website ([www.eqlpharma.com](http://www.eqlpharma.com)) and Nordic Issuing's website ([www.nordic-issuing.se](http://www.nordic-issuing.se)). The acceptance period for the Offer begins tomorrow 25 April 2023 and ends on 16 May 2023 (subject to possible extension). Payment of consideration is expected to begin around 24 May 2023.

### Information about the Offer

Information about the Offer is made available at [www.eqlpharma.com](http://www.eqlpharma.com).

### Advisors

ABG Sundal Collier AB is financial advisor to EQL Pharma in connection with the Offer. Markets & Corporate Law Nordic AB is legal advisors to EQL Pharma in connection with the Offer and Nordic Issuing AB is issuing agent in connection with the Offer.

**EQL Pharma AB (publ)**

*The board of directors*

# Press release

# EQL PHARMA

Lund, 24 April, 2023

EQL Pharma AB (publ)

556713-3425

For additional information, please contact:

Axel Schörling, CEO & President EQL Pharma AB (publ)

Phone: +46 (0) 76 317 90 60

E-mail: [axel.schorling@eqlpharma.com](mailto:axel.schorling@eqlpharma.com)

Web: [www.eqlpharma.com](http://www.eqlpharma.com)

Information about the Offer is made available at [www.eqlpharma.com/en/investors](http://www.eqlpharma.com/en/investors).

For administrative questions regarding the Offer, please contact your bank or the nominee registered as holder of your shares.

## **Important information**

*This press release has been published in Swedish and English. In the event of any discrepancy in content between the two language versions, the Swedish version shall prevail. The Offer is not being made, directly or indirectly, in or into Australia, Canada, Hong Kong, Japan, New Zealand, Singapore, South Africa or USA, or in any other jurisdiction where such offer pursuant to laws, restrictions or regulations in such relevant jurisdiction would be prohibited pursuant to applicable law, by use of mail or any other communication means or instrumentality (including, without limitation, facsimile transmission, electronic mail, telex, telephone and the Internet) of interstate or foreign commerce, or of any facility of national securities exchange or other trading venue, of Australia, Canada, Hong Kong, Japan, New Zealand, Singapore, South Africa or USA, or in any other jurisdiction where such offer pursuant to laws, restrictions or regulations in such relevant jurisdiction would be prohibited pursuant to applicable law, and the Offer cannot be accepted by any such use or by such means, instrumentality or facility of, in or from, Australia, Canada, Hong Kong, Japan, New Zealand, Singapore, South Africa or USA, or in any other jurisdiction where such offer pursuant to laws, restrictions or regulations in such relevant jurisdiction would be prohibited pursuant to applicable law. Accordingly, this press release or any other documentation relating to the Offer are not being and should not be sent, mailed or otherwise distributed or forwarded in or into Australia, Canada, Hong Kong, Japan, New Zealand, Singapore, South Africa or USA, or in any other jurisdiction where such offer pursuant to laws, restrictions or regulations in such relevant jurisdiction would be prohibited pursuant to applicable law. This press release is not being, and must not be, sent to shareholders with registered addresses in Australia, Canada, Hong Kong, Japan, New Zealand, Singapore, South Africa or USA. Banks, brokers, dealers and other nominees holding shares for persons in Australia, Canada, Hong Kong, Japan, New Zealand, Singapore, South Africa or USA, must not forward this press release or any other document received in connection with the Offer to such persons. Statements in this press release relating to future status or circumstances, including statements regarding future performance, growth and other trend projections and other benefits of the Offer, are forward-looking statements. These statements may generally, but not always, be identified by the use of words such as "anticipates", "intends", "expects", "believes", or similar expressions. By their nature, forward-looking statements involve risks and uncertainty since they relate to events and depend on circumstances that occur in the future. There can be no assurance that actual results will not differ materially from those expressed or implied by these forward-looking statements due to many factors, many of which are outside the control of EQL Pharma and Sensidose. Any such forward-looking statements speak only as of the date on which they are made and EQL Pharma has no obligation (and undertakes no such obligation) to update or revise any of them, whether as a result of new information, future events or otherwise, except for in accordance with applicable laws and regulations. However, the reader is advised to take part of any additional statements that EQL Pharma or Sensidose have made or may make in the future. ABG is not responsible to anyone other than EQL Pharma for advice in connection with the Offer.*